Table 5.
Antagonism of carbachol-induced changes by AE9C90CB, tolterodine, oxybutynin, solifenacin or darifenacin in anaesthetized rabbits
| Compound | ED50 (µg·kg−1); i.v. (mean ± SEM) | Bladder versus salivary gland selectivity (mean ± SEM) | Bladder versus salivary gland selectivity (fold of oxybutynin) | |
|---|---|---|---|---|
| Intravesicular pressure | Salivation | |||
| Oxybutynin | 49 ± 16 | 25 ± 5 | 0.6 ± 0.2*** | 1 |
| Tolterodine | 22 ± 4 | 23 ± 3 | 1.1 ± 0.2*** | 2 |
| Solifenacin | 148 ± 35*** | 194 ± 36 | 1.7 ± 0.5*** | 3 |
| Darifenacin | 6 ± 0.8 | 14 ± 0.3 | 2.3 ± 0.5*** | 4 |
| AE9C90CB | 3 ± 0.4 | 16 ± 3.4 | 5.4 ± 0.7 | 9 |
ED50 is defined as the dose inhibiting responses to 50% of control responses to carbachol and was calculated from non-linear regression analysis of percent control response using GraphPad Prism. Bladder versus salivary gland selectivity is defined as ED50 salivation/ED50 intravesicular pressure from the individual animals.
***
P < 0.001 significantly different from corresponding values for AE9C90CB; one-way anova; Tukey's multiple comparison test.